Endoplasmic reticulum (ER) Lipids rafts Oxidised low density lipoprotein (oxLDL) Palmitoylation CD36/FAT is a transmembrane glycoprotein that functions in the cellular uptake of long-chain fatty acids and also as a scavenger receptor. As such it plays an important role in lipid homeostasis and, pathophysiologically, in the progression of type 2 diabetes and atherosclerosis. CD36 expression is tightly regulated at the levels of both transcription and translation. Here we show that its expression and location are also regulated posttranslationally, by palmitoylation. Although palmitoylation of CD36 was not required for receptor maturation and cell surface expression, inhibition of palmitoylation either pharmacologically with cerulenin or by mutation of the relevant cysteines delayed processing at the ER and trafficking through the secretory pathway. The absence of palmitoylation also reduced the half life of the CD36 protein. Additionally, the CD36 palmitoylation mutant did not incorporate efficiently into lipid rafts, a site known to be required for its function of fatty acid uptake, and this reduced the efficiency of uptake of oxidized low density lipoprotein. These findings provide an added level of sophistication where translocation of CD36 to the plasma membrane may be physiologically regulated by palmitoylation.
Introduction
CD36, first identified as a plasma membrane glycoprotein on platelets and as a membrane component of milk fat globules, is a versatile molecule that can bind many ligands (reviewed in [1] [2] [3] [4] ). On macrophages and retinal epithelial cells it functions in the phagocytic uptake of apoptotic corpses and shed photoreceptor outer segment fragments, and it also engages in the endocytotic uptake of modified proteins and lipids including glycated albumin and oxidatively damaged lipoproteins [5] [6] [7] [8] [9] [10] . These latter functions in particular may account for the demonstrated role of CD36 in the development of human diabetic nephropathy [11] , and, as shown by Silverstein and colleagues in a series of mouse models, in the development and progression of atherosclerosis [12] [13] [14] . However, studies on CD36-null mice and also with transgenic mice demonstrated, primarily, an important role for CD36 in lipid homeostasis, validating the earlier findings of Abumrad and colleagues who had isolated and identified a facilitator of long chain fatty acid (LCFA) uptake in rat adipocytes and named it FAT, for fatty-acid translocase [15] . CD36/FAT-null mice exhibit increased fasting levels of cholesterol, triacylglycerol and LCFA, and hypoglycaemia [16] . Conversely, transgenic mice overexpressing CD36 in skeletal muscle were lean with less adipose tissue, had reduced triglycerides and LCFAs, and significantly elevated plasma glucose levels [17] . Substantiating these findings in mice, the SHR/NIH spontaneously hypertensive rat which exhibits multiple metabolic disorders similar to the human dysmetabolic syndrome was found to contain a deletion variant of CD36 [18] . Numerous in vitro studies with isolated tissues, and with muscle cells, cardiomyocytes and adipocytes have now established a direct role for CD36 in LCFA uptake by these cell types [15, 17, [19] [20] [21] [22] [23] although the mechanism of uptake remains to be determined. Critical to this and perhaps other CD36-mediated functions is the localisation of the protein to plasma membrane lipid raft domains [22] .
The CD36 sequence indicates an unusual structure for this molecule. It contains an uncleaved signal peptide at the amino terminus and a transmembrane domain followed by a short predicted carboxyl terminus and, in their original cloning paper, Oquendo et al. [24] doubted that the uncleaved signal sequence was sufficient to provide a membrane anchor. Lublin and colleagues addressed this topology issue by mutagenizing the pairs of juxtamembrane cysteines at either end of the molecule and showing that all four were palmitoylated in human embryonic kidney cells, indicating their cytosolic location and, thereby, a horseshoe topology for CD36 [25] . It had been known for some time that CD36 was palmitoylated, since the work of Jochen and Hays showing that in adipocytes CD36 was the dominant marker for palmitoylation in adipocytes, and that this palmitoylation was greatly increased by treatment of the cells with insulin [26] . Furthermore, insulin also rapidly stimulates the surface expression of CD36 in muscle cells [27, 28] . However, the functional consequences of palmitoylation of this highly hydrophobic molecule have never been addressed. We undertook the present study anticipating that dynamic palmitoylation might serve to regulate CD36 function at the plasma membrane. Our findings, however, indicate that palmitoylation of CD36 influences the expression and location of the molecule at a more basic level, suggesting that this post-translational modification serves as an additional regulator of functional expression at the cell surface.
Materials and methods

Cell lines, expression constructs and transfections
The WM115 and MV3 human melanoma, RD rhabdomyosarcoma and COS-7 cell lines were maintained as described previously [29, 30] . Stable transfection of MV3 cells was performed by co-transfection with pREP9 and either pEF.BOS empty vector (MV3.BOS) or pEF.BOS containing wildtype CD36 cDNA (MV3.CD36) or the non-palmitoylated AA-SS mutant (MV3.AA-SS) described in Thorne et al. [30, 31] . Transient transfections were performed by electroporation as previously described [31] .
Antibodies
Monoclonal antibodies (mAb) against CD36 (VM58, 11H5, Mo25 and Long 9), control anti-human μ-chain mAb (HB57), FMC-56 anti-CD9 mAb, anti-DAF mAb, affinity purified polyclonal antibodies against CD36 and β1-integrin, polyclonal anti-caveolin-1 and polyclonal anti-calreticulin have been described previously [29, 30, [32] [33] [34] . Antibodies against calnexin and the Golgi SNARE protein Vti1a were purchased from (Transduction Labs, Lexington, KY).
Flow cytometry and immunofluorescence microscopy
Surface antigen expression analysis was performed on trypsin-versene harvested cell suspensions as previously described [30] . Immunofluorescence microscopy was performed as previously described on cells attached to glass coverslips [34] .
In vivo cell labeling
For labeling experiments with palmitate, cell monolayers were rinsed with DMEM supplemented with 10 mg/ml fatty acid free (FAF) BSA (ICN Biomedicals) and then pre-incubated in the FAF-media for 30 min at 37°C. This medium was then removed and replaced with FAFmedium containing either 1 mCi/ml 35 S-methionine/cysteine or 3 Hpalmitic acid (DuPont-NEN). To concentrate the palmitate label from the ethanol stock solutions, each was dried under vacuum and redissolved in DMSO before adding to labelling medium at a final DMSO concentration of 0.3% (v/v). The cells were lysed and immunoprecipitations performed as previously described [31] . Incorporation of the radiolabel was assessed by fluorography using Amplify (Amersham) after SDS-PAGE. Pulse-chase labeling experiments with 35 S-methionine/ cysteine were conducted as previously described [33] .
Streptavidin capture of surface biotinylated proteins
Cell surface antigens were first labelled with biotinamidocaproate Nhydroxysuccinimide ester (Sigma) as described previously [30] . Soluble cell lysates were then prepared and adsorbed to streptavidin-coupled agarose beads (Sigma). The beads were then extensively washed with high salt RIPA buffer before elution of the beads with sample buffer. Following resolution by SDS-PAGE and transfer to nitrocellulose, immunoblotting was performed [34] .
Subcellular fractionations
Analyses were performed by ultracentrifugation using gradients of iodixanol (Optiprep, Axis-Shield). Cell suspensions in HB (0.25 M sucrose, 1 mM EDTA, 20 mM Hepes-NaOH, pH 7.4) containing protease inhibitors (Roche) prepared from 360 to 540 cm 2 cultures were homogenised by nitrogen cavitation in a Parr 45 mL cell disruption bomb (550 psi, 15 min; Parr Instruments). Cell nuclei and heavy organelles were removed from the homogenate by sequential centrifugation at 1000g and 10,000g, respectively, before preparation of a 100,000g membrane pellet (P100). This material was thoroughly resuspended in HB before being overlaid onto a pre-formed linear 10-30% of Optiprep prepared in HB before centrifugation for 2 h at 100000 ×g in an SW41Ti rotor (Beckman-Coulter). Fifteen equal fractions were collected from the bottom of each tube. Where indicated the immunoprecipitates were digested with endoglycosidase H according to the manufacturer's instructions (New England Biolabs).
Isolation and analysis of detergent-resistant membranes
DRMs were prepared by floatation on sucrose density gradients by ultracentrifugation of Triton X-100 lysates as previously described [30, 31] . Fractions were collected from the top of the gradient and equal protein amounts from each fraction were analysed by immunoblotting. In some experiments the partitioning of CD36 to the DRM and other fractions was determined using densitometric analysis using MultiGuage software (Fuji Imaging). Statistical analysis was performed using the Student's t-test.
Bivariate analysis of oxLDL uptake
DiI (1,1'-diotadecyl-3-3-3'-3'-tetramethyllindocarbocyanine percholorate) labeled oxLDL was purchased from Intracel Corporation (Rockville, MD) and incubated with the MV3 cells as indicated. Cells were then harvested with trypsin-versene solution, immunostained on ice with VM58-FITC (anti-CD36) before data acquisition using a FACScan flow cytometer (Becton-Dickinson) using the FL2 or FL1 emission filters for DiI and FITC, respectively. In some assays human transferrin uptake (Sigma; labelled with FITC isomer 1 (Calbiochem)) was compared with CD36 levels detected with an anti-mouse PE conjugate. The data were exported and analysed using the bivariate spreadsheet method as reported previously [35] .
Briefly, all cell event data are categorised according to the levels of expression of receptor (CD36). After excluding channels with zero or low frequency of cell events, the average fluorescence values for (DiIoxLDL or transferrin) ligand uptake are calculated for each receptor level category and the results plotted. To compare samples, the spreadsheet incorporates a Student's t-test that compares the uptake of ligand for receptor categories displaying equivalent receptor expression.
Results
3.1.
A non-palmitoylated AA-SS mutant of CD36 is expressed at the plasma membrane in the correct conformation CD36 has been demonstrated previously to be palmitoylated on a pair of cysteines at either end of the molecule, adjacent to putative transmembrane domains [25] . To confirm that these cysteines accounted for the total palmitoylation of CD36, we prepared a mutation in which the cysteine pair toward the aminoterminus were substituted with alanines, and those towards the carboxyl terminus with serines (AA-SS mutation; Fig 1A) . Constructs were then transfected into COS-7 cells, selected for analysis since they express abundant protein after transfection thus permitting reasonable fluorography times when using fatty acids labelled with weak β-emitting isotopes. Two days following transfection, a proportion of the cells were stained for CD36 by flow cytometry and these analyses revealed comparable levels of surface expressed protein for each transfected product (Fig 1B) .
The remaining cells were equally divided then metabolically labelled with 35 S-cysteine/methionine as a measure of total protein, or with 3 H-palmitic acid to measure palmitoylation. The cells were lysed and immunoprecipitated for CD36 and, sequentially, for CD9, a molecule endogenously expressed by COS-7 cells and known to be palmitoylated [36] . Immunoprecipitates were resolved by SDS-PAGE and labelled proteins determined by fluorography. As shown in Fig. 1C the Cys/Met labelling of the internal control, CD9, indicating equivalent levels of protein expression. As anticipated from the work of Tao et al. [25] , the palmitate label was incorporated into wt CD36 but not into the AA-SS mutant, and this work together with our analysis of a panel of cysteine-substitution mutants (data not shown) confirmed that the four cytoplasmic cysteine residues account for the entire palmitoylation of CD36.
We then measured the expression and conformation of the AA-SS mutant in more physiologically relevant cells. In vivo, most melanoma and muscle tissues express CD36 [37, 38] therefore we selected the MV3 melanoma cell line and the RD rhabdomyosarcoma cell lines for our transfection experiments since they lack endogenous CD36 expression although other cultured melanoma cell lines as well as other isolates of RD cells do display high levels of endogenous CD36 ( [30] ; data not shown). The MV3 cells were stably transfected with wt CD36 and the AA-SS constructs and after selection in G418, the surface expression of CD36 was analysed with a conformational dependent mAb (VM58) that identifies only the correctly folded mature molecule [33] . However, a difference in cell surface expression of CD36 was found between the AA-SS and wt expressing cells in that-in order to achieve comparably high levels of surface expression to the wt CD36-expressing cells-the AA-SS-expressing cells had to be enriched for high expression by several rounds of fluorescence-activated cell sorting. Thus although able to achieve high levels of surface expression, this finding suggests that the expression of the AA-SS mutant may be less stable than that of wtCD36 in the transfected MV3 cells. After such selection, however, as shown in Fig. 2 and in data not shown, whether analysed by flow cytometry ( Fig. 2A ) or immunofluorescent microscopy ( Fig. 2B ) using antibodies that recognise the mature CD36 conformation, the wt and AA-SS transfected MV3 cells expressed equivalent CD36 protein at the cell surface. An independent method, biotinylation of the cell surface ( Fig. 2C ) confirmed these results with the only difference noted being a slight reduction in electrophoretic mobility of the AA-SS relative to wt CD36 protein.
Palmitoylation is required for efficient processing and ER to Golgi trafficking of CD36
Next we examined the synthesis and glycosylation of the AASS mutation of CD36 using pulse-chase analysis. Alessio et al. [39] have carried out a detailed analysis of the synthesis, processing and intracellular transport of CD36 in monocytic cell lines, and these authors established the precursor relationships of a 74 kDa species that matures to the larger molecule found on the cell surface; however they also noted that the rate of processing could vary significantly between different cell lines. For this reason we first assessed the synthesis and processing of the endogenous CD36 in WM115 melanoma cells in pulse-chase analyses. The results demonstrated the expected precursor CD36 product(s) converting to the mature protein during the chase period, with the half life of the precursor protein found to be around 120 min (Fig. 3A) . We then compared the rate of conversion in MV3 cells stably expressing wt CD36 or the AA-SS mutant. The results illustrated in Fig. 3B show that the rate of conversion from the precursor to the mature CD36 molecule was substantially the same as the endogenous protein in MV3 cells expressing wt CD36 (at around 90 min for 50% conversion); however this process was considerably slowed in cells expressing the AA-SS mutant. In these cells normal processing did occur, but the appearance of the mature molecule was substantially delayed such that the time required for 50% conversion of the precursor was extended to around 4 h (Fig. 3B) . Very similar results were obtained with transiently transfected RD cells where the appearance of the mature band also was delayed by 1-2 h in the AA-SS expressing cells (Suppl. Fig. 1 ).
These results suggest that palmitoylation of CD36 is required for efficient conversion of the CD36 precursor into the mature molecule. This notion was substantiated by immunoblotting of whole cell lysates from the stably transfected MV3 melanoma cells when the precursor band was seen clearly to accumulate in the AA-SS-expressing cells but not in those expressing wt CD36 (Fig. 3C) . Moreover, the persistent band was not (Fig. 2C) , a result entirely consistent with the interpretation that this represents the~74 kDa CD36 precursor. However, there is a polymorphism of CD36, a proline to serine substitution at position 90, which results in the failure of expression at the cell surface of some cell types, and this has been attributed to a folding defect causing the precursor protein to be retained in the ER [40] . In addition, we have found that a number of other mutations to CD36 cause a similar folding defect in MV3 cells (data not shown), therefore it was important to establish that the failure of maturation of the AA-SS mutation is a consequence of the absence of palmitoylation and not of the mutations themselves. To test this pharmacologically we used the mycotoxin, cerulenin, since this natural antibiotic has been shown previously to block palmitoylation of CD36 in rat adipocytes [41] . After treatment of the MV3 cells stably expressing wt CD36 with cerulenin at a non-toxic dose (5 μg/ml; Suppl. Fig. 2 ), it was found by Western blotting that this similarly resulted in the appearance of the lower, precursor band in a dose-dependent manner (Fig. 3D) . The reduction in electrophoretic mobility infers that palmitoylation of CD36 had been partially inhibited by cerulenin, and taken together with the results obtained with the AA-SS mutational analysis showing the persistence of the CD36 precursor molecule, it can be concluded that palmitoylation of CD36 is important for the efficient maturation of the mature cell surface expressed molecule.
Although the 74 kDa band has been established as a precursor of the mature protein in pulse-chase experiments (Fig. 3) [39] , the location and nature of this molecule has not been examined previously. To begin this process we prepared total membranes from stable MV3 transfectants by nitrogen cavitation and further separated these on Optiprep gradients to differentially separate ER, Golgi and plasma membranes. Individual fractions collected from both the wt CD36 and AA-SS expressing cells were then blotted for calnexin as a marker for the ER, with VTi1a as a Golgi marker, and also with a mAb against CD36 (Fig. 4A) . The results show that whereas wt CD36 is distributed across the gradient, the location of the precursor band seen in the AA-SS mutant is largely coincident with the ERenriched fractions. Further evidence for the ER location of this precursor band was obtained by treating similar fractions with endoglycosidase (Endo)H before analysis: this enzyme cleaves only high mannose sugars before they are processed in the medial Golgi and, thus, sensitivity to cleavage generally indicates an ER localisation. In these experiments ( Fig. 4B and C ) a low proportion (~10%) of the wt CD36 located in the fractions containing ER membranes was subject to EndoH cleavage. In contrast, samples from the AA-SS expressing cells showed a much high degree of sensitivity to EndoH-treatment, indicated by the prominent appearance of a band at~53 kDa that corresponds to the size of the core CD36 protein (Fig 4B) . Also evident in Fig. 4B is the almost complete disappearance of the precursor band in the EndoH treated samples, a result consistent with the entire precursor band being digested by this enzyme. These results show that the CD36 precursor that persists in the AA-SS mutant has failed to reach the medial Golgi for further processing and is likely retained at the ER. The results also established that the smaller size of the precursor is caused by a difference in glycosylation, because the larger EndoH-sensitive form and the smaller precursor both migrate to the same Mr after EndoH treatment.
Palmitoylation is required for efficient incorporation into membrane rafts
CD36 was one of the first membrane proteins shown to locate to plasma membrane rafts in endothelial cells [42] , identified biochemically as detergent resistant membranes, DRMs [43] , and subsequently a raft localization for CD36 has been shown in several cell types [30, 31, 44] . We carried out similar DRM analysis of wt CD36 and AA-SS to determine whether this localization of CD36 was similarly influenced by palmitoylation. First, we established that endogenous CD36 expressed by melanoma cells was enriched in DRM fractions upon sucrose gradient analysis, and this was shown to be the case for WM115 melanoma cells (Fig. 5A) . Examination of the transfected MV3 cells in the same way showed wt CD36 to be highly enriched within the visible floating band that also contained caveolin (Fig. 5B and Suppl. Fig. 3 ) consistent with our previous analysis [30] . By contrast, the AA-SS protein was less evident within the DRM fractions and was most strongly expressed in fraction 6, a position on the gradient that was intermediate between the DRM fractions and the soluble fractions (Fig. 5B) . Both wt and AA-SS showed only trace amounts across the soluble fractions that contained the ER protein, calreticulin. Densitometric analysis of multiple isolations confirmed the altered distribution of the AA-SS to the intermediate fraction to be a consistent statistically significant finding (Fig. 5C ). Very similar results were obtained using transiently transfected RD cells that displayed strong enrichment of the AA-SS protein to intermediate density fractions (Fig. 5D) .
To ensure that these results were a direct consequence of the loss of palmitoylation and not the effects of the substitution mutations in the AA-SS protein, we again employed pharmacologic inhibition of palmitoylation. Treatment of the MV3.CD36 cells with cerulenin showed a modest but significant reduction in the amount of CD36 protein localising to DRMs when normalised against DAF, a GPI-linked (i.e. non-palmitoylated) protein known to isolate to DRMs (Fig. 5E ). Due to the toxicity limitations of treating MV3 cells with cerulenin (Suppl. Fig. 2 ) and its partial effectiveness at inhibiting palmitoylation (Fig. 3D) , these results infer that the palmitoyl-modification of CD36 is required for efficient incorporation into membrane raft domains.
Palmitoylation influences the uptake of lipids from oxidised low density lipoprotein by CD36
As described in Introduction, the localisation of CD36 to DRMs has known functional consequences with respect to the uptake of FA [22] . In previous we work we have established that CD36 transfection of MV3 cells was sufficient to elicit enhanced uptake of lipids from oxidatively damaged lipoproteins [10] . Microscopic examination of the uptake oxLDL showed that the AA-SS receptors were not functionally deficient since these transfectants took up much more oxLDL than control vectortransfected cells. Although both the CD36 and AA-SS transfected MV3 cells were able to uptake DiI-labelled oxLDL with a similar distribution of the DiI within cytoplasmic vesicles, some MV3.AA-SS cells appeared to uptake less fluorophore (Fig. 6A) . We therefore sought to investigate the effect of palmitoylation on CD36 function by examining the uptake of oxLDL in a quantitative assay.
For this we applied a bivariate flow cytometric assay, a technique developed to overcome the bias of differences in receptor expression in cell based ligand binding assays [35] . MV3-CD36 and AA-SS cells were preloaded with 1-25 μg/ml DiI-labelled oxLDL before transferring the cells to ice and staining for CD36 expression using a mAb directly coupled to fluorophore. Flow cytometry was performed and the data analysed using the bivariate method (Fig. 6B ). There was a significant decrease in the uptake of lipids as reported by the DiI lipid analogue in the AA-SS cells relative to wt CD36 evaluated across the range of CD36 surface expression levels, with increasing differences between wt CD36 and AA-SS with increasing ligand loading (Student's t-test, Fig. 6B(i)-(v) ). As further validation of this assay we undertook a comparison of the MV3.CD36 and AA-SS cells using transferrin uptake. Transferrin is readily taken up by MV3 cells but in this capacity serves as a control ligand whose receptor system is independent of CD36 function. There were little differences between CD36 and AA-SS expressing cells in this assay (Fig. 6B(vi) ). Taken together these results show that the palmitoylation of CD36 influences the efficiency of uptake of oxLDL, possible in consequence of its role in targeting the molecule to plasma membrane rafts.
Discussion
In this study we demonstrate the multifaceted effects of palmitoylation on the transmembrane glycoprotein, CD36/FAT and suggest these provide a novel regulatory function. We show that in the absence of palmitoylation in melanoma cells and rhabdomyosarcoma cells, posttranslational processing is considerably delayed at the ER. Additionally we determine that in the absence of palmitoylation CD36 is also poorly incorporated into plasma membrane rafts and, perhaps in consequence, displays reduced efficiency of uptake of its ligand, oxLDL. Therefore our results suggest that, in the context of CD36, palmitoylation provides several mechanisms of control, both the efficiency of receptor maturation, the correct localisation at the plasma membrane and the uptake of ligand. Such findings point to possible aspects important to the physiological functioning of CD36.
It has been known since the work of Jochen and Hays over a decade ago that CD36 is the major substrate for palmitoylation in adipocytes, and that this palmitoylation was increased by insulin stimulation and inhibited by cerulenin [26, 41] . Also treatment of adipocytes with cerulenin inhibits surface expression of CD36 [45] , results consistent with our data showing that the inhibition of acylation by cerulenin inhibits the maturation state of CD36. Moreover, abrogation of palmitoylation by mutation resulted in the accumulation of the CD36 precursor molecule in the endoplasmic reticulum. Similar findings of a requirement for palmitoylation for proper intracellular sorting and forward transport have been obtained by Berthiaume and colleagues in their studies of apolipoprotein B [46, 47] . These authors suggest that the levels of palmitoyl-CoA, the substrate for palmitoyltransferases (PAT) enzymes, may act as a molecular sensor for the availability of newly synthesised neutral lipids, thereby coordinating this with secretion. Since CD36 is a major receptor in the uptake of LCFA that subsequently can also be utilized by PAT enzymes, an attractive hypothesis is that high levels of circulating LDL will promote CD36 expression and function to reduce these levels by endocytosis. Berthiaume and colleagues also suggest that the palmitoylation of apoB serves to localize it to subcompartments of the ER rich in neutral lipids. It is possible that CD36 accumulates in such subcompartments of the ER, directed by palmitoylation, and that these sub-compartments are then targeted together to the Golgi regions believed to be involved in raft formation [48] .
Interestingly, we noted that in the absence of palmitoylation CD36 was enriched in intermediate density fraction(s) of the sucrose gradients (Fig. 5) . The origin of this region is not known but preliminary blotting experiments across the gradient from lysates of transfected MV3 cells labeled on the surface with biotin indicate that they represent internal rather than surface material (Suppl. Fig. 4A ), and these fractions are also relatively enriched in GS28 (a Golgi marker; Suppl. Fig. 4C ). The Golgi apparatus is thought to represent the site of lipid raft formation [48] but the intracellular pool of FAT/CD36 from fibroblasts that fractionates with the Golgi was reported to not be associated with lipid rafts [22] . Such a mechanism would be consistent with our findings that in the absence of palmitoylation, forward trafficking and maturation of the AA-SS mutant through the secretory pathway is retarded, and perhaps in consequence of this, the mutant CD36 protein fails to efficiently localize to raft domains. We previously determined that the tetraspanins CD9 and CD63, also subject to extensive modification by palmitoylation, were also enriched in intermediate density fractions [30] but it will require further analysis to establish whether this biochemical localisation truly represents the Golgi or some other physiological compartment.
Our results also infer that that CD36 is most likely palmitoylated at the ER as evidenced by the subcellular fractionation studies presented in Fig. 4 . The substrate specificity of the large family of mammalian PAT enzymes are poorly understood, but in yeast, Swf1, a member of the DHHC-CDR family PATs, has been identified as being responsible for the palmitoylation of most transmembrane proteins that are modified at cysteine residues close to the cytoplasmic end of the transmembrane domain [49] . Swf1 is localized at the ER, and a deletion mutation of this enzyme-resulting in a failure of palmitoylationcauses the substrate TM containing proteins to be ubiquitinated, missorted and degraded. In our experimental system we have driven CD36 expression with a powerful EF promoter enabling high levels of expression in the absence of the normal regulators and, together with selection by cell sorting, this was sufficient to drive high cell-surface expression of the AA-SS mutant in melanoma cells. However, comparative examination of these cells after cycloheximide treatment was able to confirm that the half life of the AA-SS protein was less than wt CD36 (Suppl. Fig. 5 ) supporting the notion that in the absence of [35] . (i-v) Cells were incubated with 1-25 μg/ml DiI-OxLDL as indicated for 3 h at 37°C and counterstained with VM58-FITC for CD36 cell surface expression before analysis. The data shown are representative of those obtained on 3 separate occasions. (vi) Uptake assay using FITClabeled transferrin (25 μg/ml for 30 min at 37°C) in MV3.CD36 and AA-SS cells. Transferrin is a ligand readily taken up by MV3 cells but whose uptake is irrelevant to the function of CD36. The black points plotted across the abscissa flag significant differences in ligand uptake values occurring between MV3.CD36 and MV3.AA-SS cells displaying equivalent CD36 expression levels (Student's t-tests reaching the 99.9% confidence value). For the transferrin assays there were few significant differences between CD36 and AA-SS expressing cell populations in two independent assays (only 9 of 800 fluorescence channels reaching significance) compared to the results observed for the DiI-oxLDL experiments where a dose dependent response was observed.
palmitoylation (the AA-SS mutant) was more rapidly destroyed, possibly consistent with the regulatory mechanism defined by Swf1 in yeast. Whether the AA-SS protein is subject to proteosome degradation or other mechanisms (e.g. lysosomal degradation) is not known but our findings nevertheless support the general concept that palmitoylation of CD36 imparts regulatory effects regarding its incorporation into the secretory pathway.
Our second main finding was that palmitoylation was substantially required for the enrichment of CD36 into DRMs representing plasma membrane rafts. This property has long been established for the membrane targeting of soluble proteins: for example, in p59fyn dual acylation with myristate and palmitate was necessary for targeting into DRMs [50] . However, the DRM targeting role of acylation for transmembrane proteins such as CD36 are not so well defined or predictable given the great variety of topological subclasses of membrane proteins and indeed their extent of acylation. For example while palmitoylation of the transmembrane proteins α6β4 integrin and CD4, imparts partitioning to DRMs/rafts [51] [52] [53] , there are other examples where this modification is not sufficient for targeting, e.g. LMP2A and claudin [54, 55] . Whilst the palmitoylation of CD36 has been recorded [25] , to our knowledge this targeting mechanism(s) for incorporation to DRMs has not been previously reported for CD36 or any of members of its gene family.
The absence of palmitoylation of CD36 also had functional consequences in the reduced efficiency of uptake of oxLDL; this was an expected finding since other workers have demonstrated that the function of CD36 in the uptake of long-chain fatty acids depends upon its localization to plasma membrane rafts and, indeed, the binding of a FA-analogue to CD36 at the plasma membrane occurred only within DRMs [22] . Our findings suggest that CD36 requires a similar localisation for the efficient uptake of oxLDL. This requirement for localisation to DRMs for efficient oxLDL uptake may in part reflect the conformation of CD36 in this lipid-rich environment. Previous studies have shown that mutation of the carboxylterminal cysteines, either singly or as a pair, was unable to inhibit the CD36-dependent uptake of oxLDL whereas carboxylterminal truncation mutants displayed decreased efficiency [56] . Additionally, Eyre and colleagues reported that truncation of the carboxylterminal domain, inclusive of two of the four palmitoylated cysteines, did not influence the enrichment to DRMs but did prevent CD36-mediated FA uptake [21] . While our own data ( Fig. 1C and data not shown) and that of others [25] have shown that mutation of all four cysteines (2 aminoterminal and 2 carboxylterminal) are necessary to abrogate palmitoylation of CD36, our analysis of truncated CD36 constructs similar to those used in these reported studies found that these mutations do not abrogate palmitoylation (data not shown).
How then might our findings contribute to the better understanding of the physiological regulation and function of CD36? CD36 expression is known to be regulated at the transcriptional level by PPARγ and by the pregnane X receptor (PXR) [57, 58] , important regulators of lipid homeostasis. In turn, translation of CD36 mRNA is regulated by the availability of glucose [59] . Other important molecules engaged in lipid homeostasis are also regulated by PPARγ, and the levels of PPARγ and insulin as well as CD36 are regulated by glucose [59] [60] [61] . Thus an interconnected series of regulators coordinate the expression of different components involved in lipid homeostasis. Our results suggest that in addition to the currently known transcriptional and translational regulatory mechanisms, the palmitoylation requirement for functional CD36 expression represents an additional element of fine tuning.
